The Division of AIDS of the National Institute of Allergy andInfectious Diseases plans to compare the safety andimmunogenicity of a recombinant HIV envelope proteinvaccine formulation incorporating MPL immunostimulant withsimilar formulations incorporating other adjuvants in a Phase Iclinical study, Ribi ImmunoChem said Thursday. The trial willinclude volunteers who are not infected with HIV.

The AIDS Vaccine Evaluation Group will conduct the study,which is intended to compare vaccine formulations based on arecombinant rgp120 HIV envelope protein antigen. Thecomparison will determine the safety and immunogenicity offive vaccine formulations, the Hamilton, Mont., company(NASDAQ:RIBI) said.

Ribi is developing immunostimulants for preventing andtreating human and animal diseases.

(c) 1997 American Health Consultants. All rights reserved.